000136290 001__ 136290
000136290 005__ 20250923084420.0
000136290 0247_ $$2doi$$a10.1111/hel.13111
000136290 0248_ $$2sideral$$a139257
000136290 037__ $$aART-2024-139257
000136290 041__ $$aeng
000136290 100__ $$aMartínez-Domínguez, Samuel J.$$uUniversidad de Zaragoza
000136290 245__ $$aIndications of Helicobacter pylori eradication treatmentand its influence on prescriptions and effectiveness (Hp-EuReg)
000136290 260__ $$c2024
000136290 5060_ $$aAccess copy available to the general public$$fUnrestricted
000136290 5203_ $$aBackground:
The influence of indications for Helicobacter pylori investigation on prescriptions and effectiveness is unknown. The aim of the study was to assess the impact of indications for H. pylori investigation on prescriptions, effectiveness, compliance, and tolerance.
Methods:
International, prospective, non-interventional registry of the management of H. pylori infection by European gastroenterologists (Hp-EuReg). Treatment-näive patients registered from 2013 to 2023 at e-CRF AEG-REDCap were analyzed. The effectiveness was assessed by modified intention-to-treat analysis.
Results:
Overall, 53,636 treatment-naïve cases from 34 countries were included. Most frequent indications were: dyspepsia with normal endoscopy (49%), non-investigated dyspepsia (20%), duodenal ulcer (11%), gastric ulcer (7.7%), and gastroesophageal reflux disease (GERD) (2.6%). Therapy effectiveness varied by indication: duodenal ulcer (91%), gastric ulcer (90%), preneoplastic lesions (90%), dyspepsia with normal endoscopy (89%), GERD (88%), and non-investigated dyspepsia (87%). Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies achieved 90% effectiveness in all indications except GERD. Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole reached 90% cure rates except in patients with non-investigated dyspepsia; whereas sequential clarithromycin-amoxicillin-tinidazole/metronidazole proved optimal (≥90%) in patients with gastric ulcer only. Adverse events were higher in patients treated for dyspepsia with normal endoscopy and duodenal ulcer compared with the remaining indications (23% and 28%, p < 0.001). Therapeutic compliance was higher in patients with duodenal ulcer and preneoplastic lesions (98% and 99%, p < 0.001).
Conclusion:
In Europe, patients with gastric or duodenal ulcers and preneoplastic lesions showed higher H. pylori treatment effectiveness. Bismuth and non-bismuth quadruple therapies achieved optimal results in almost all indications.
000136290 536__ $$9info:eu-repo/grantAgreement/EC/HORIZON EUROPE/101095359/EU/An Artificially Intelligent Diagnostic Assistant for gastric inflammation/AIDA
000136290 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000136290 590__ $$a4.3$$b2024
000136290 592__ $$a1.174$$b2024
000136290 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b30 / 147 = 0.204$$c2024$$dQ1$$eT1
000136290 593__ $$aGastroenterology$$c2024$$dQ1
000136290 591__ $$aMICROBIOLOGY$$b45 / 163 = 0.276$$c2024$$dQ2$$eT1
000136290 593__ $$aMedicine (miscellaneous)$$c2024$$dQ1
000136290 593__ $$aInfectious Diseases$$c2024$$dQ1
000136290 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000136290 700__ $$aNyssen, Olga P.
000136290 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Ángel$$uUniversidad de Zaragoza
000136290 700__ $$aAlfaro, Enrique$$uUniversidad de Zaragoza
000136290 700__ $$aJonaitis, Laimas
000136290 700__ $$aMahmudov, Umud
000136290 700__ $$aVoynovan, Irina
000136290 700__ $$aGülüstan, Babayeva
000136290 700__ $$aRodrigo, Luis
000136290 700__ $$aFiorini, Giulia
000136290 700__ $$aPerez-Aisa, Ángeles
000136290 700__ $$aTejedor-Tejada, Javier
000136290 700__ $$aTepes, Bojan
000136290 700__ $$aVologzanina, Ludmila
000136290 700__ $$aMammadov, Emin
000136290 700__ $$aLerang, Frode
000136290 700__ $$aOglu, Quliyev F¿rid Vidadi
000136290 700__ $$aBakulina, Natalia V.
000136290 700__ $$aAbdulkhakov, Rustam
000136290 700__ $$aTatiana, Ilchishina
000136290 700__ $$aButler, Thomas J.
000136290 700__ $$aSarsenbaeva, Aiman Silkanovna
000136290 700__ $$aBumane, Renate
000136290 700__ $$aLucendo, Alfredo J.
000136290 700__ $$aRomano, Marco
000136290 700__ $$aBujanda, Luis
000136290 700__ $$aAbdulkhakov, Sayar R.
000136290 700__ $$aZaytsev, Oleg
000136290 700__ $$aPabón-Carrasco, Manuel
000136290 700__ $$aKeco-Huerga, Alma
000136290 700__ $$aDenkovski, Maja
000136290 700__ $$aHuguet, Jose M.
000136290 700__ $$aPerona, Monica
000136290 700__ $$aNúñez, Óscar
000136290 700__ $$aPavoni, Matteo
000136290 700__ $$aFadieienko, Galyna
000136290 700__ $$aAlekseenko, Sergey
000136290 700__ $$aSmith, Sinead M.
000136290 700__ $$aHernández, Luis
000136290 700__ $$aKupcinskas, Juozas
000136290 700__ $$aBordin, Dmitry S.
000136290 700__ $$aLeja, Marcis
000136290 700__ $$aGasbarrini, Antonio
000136290 700__ $$aGridnyev, Oleksiy
000136290 700__ $$aCano-Català, Anna
000136290 700__ $$aParra, Pablo
000136290 700__ $$aMoreira, Leticia
000136290 700__ $$aMégraud, Francis
000136290 700__ $$aO'Morain, Colm
000136290 700__ $$aGisbert, Javier P.
000136290 700__ $$a
000136290 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000136290 773__ $$g29, 4 (2024), e13111 [16 pp.]$$pHelicobacter$$tHELICOBACTER$$x1083-4389
000136290 8564_ $$s6057493$$uhttps://zaguan.unizar.es/record/136290/files/texto_completo.pdf$$yVersión publicada
000136290 8564_ $$s3061627$$uhttps://zaguan.unizar.es/record/136290/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000136290 909CO $$ooai:zaguan.unizar.es:136290$$particulos$$pdriver
000136290 951__ $$a2025-09-22-14:35:14
000136290 980__ $$aARTICLE